NICE Rapid Evidence summary for anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis

Gary Hodgson, Medicines Information Pharmacist, North West Medicines Information CentrePublished Last updated See all updates

A summary of the evidence on the use of anakinra for treatment of haemophagocytic lymphohistiocytosis secondary to COVID-19 infection.

Advice and material

The National Institute for Health and Care Excellence (NICE) has produced a rapid evidence summary on use of Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis.

Haemophagocytic lymphohistiocytosis

Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome, which can lead to a cytokine storm, tissue damage and multi-organ failure. It has a high mortality rate. Viral infections are the most common cause of secondary HLH (sHLH).

A hyperinflammatory response develops in some people with COVID-19, which may be localised to the lungs or lead to widespread systemic illness and sHLH.

Anakinra

Anakinra is recommended (off label) in treatment algorithms for sHLH as part of a multi-disciplinary team decision-making process. In critical illness, subcutaneous absorption can be unreliable and intravenous dosing is sometimes used in clinical practice to achieve a higher and faster maximal plasma concentration (it is not licensed for intravenous administration).

Anakinra and COVID-19

At the time of the review, no relevant papers were identified in the searches undertaken for this evidence review. Therefore, no evidence is available to determine whether anakinra is effective, safe or cost effective for treating adults and children with sHLH triggered by SARS-CoV-2 or a similar coronavirus.

At this time, policy decisions on whether anakinra should be used for treating COVID-19 associated sHLH will need to consider data extrapolated from studies assessing anakinra for related conditions, such as macrophage activation syndrome, non-coronavirus sHLH and hyperinflammation in people with COVID-19 and acute respiratory distress syndrome (ARDS).

All COVID-19 Specialty Summaries

COVID-19 Specialty Summaries

Clinical specialty guidance for medicines and COVID-19 summarised from a range of professional and government bodies

Change history

  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Page checked and remains current
  1. Title clarified and other editorial changes.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Published